Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 5 | 2024 | 317 | 1.620 |
Why?
|
| Neoplasms | 7 | 2024 | 3171 | 0.980 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2368 | 0.780 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 774 | 0.770 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 1073 | 0.680 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 129 | 0.670 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 17 | 0.670 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 63 | 0.650 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 555 | 0.580 |
Why?
|
| MicroRNAs | 1 | 2023 | 580 | 0.560 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1133 | 0.510 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 620 | 0.460 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 1054 | 0.440 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 1077 | 0.420 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 300 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3158 | 0.280 |
Why?
|
| Humans | 22 | 2025 | 93607 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 2544 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 2 | 2025 | 446 | 0.220 |
Why?
|
| Motor Neuron Disease | 2 | 2014 | 20 | 0.220 |
Why?
|
| DNA, Viral | 1 | 2025 | 234 | 0.210 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 1061 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 76 | 0.210 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2023 | 29 | 0.200 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.200 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2025 | 149 | 0.200 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 132 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 105 | 0.190 |
Why?
|
| Chemoradiotherapy | 1 | 2025 | 326 | 0.190 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.180 |
Why?
|
| Fluorouracil | 1 | 2023 | 524 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 554 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 395 | 0.160 |
Why?
|
| Pneumonia | 1 | 2022 | 193 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 2018 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 1449 | 0.150 |
Why?
|
| Motivation | 1 | 2022 | 310 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2023 | 10186 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 416 | 0.140 |
Why?
|
| Female | 9 | 2025 | 48771 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 490 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 504 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1661 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 711 | 0.120 |
Why?
|
| Cerebellum | 2 | 2014 | 248 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2014 | 324 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1723 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2025 | 4563 | 0.110 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2014 | 23 | 0.110 |
Why?
|
| Brain Mapping | 2 | 2014 | 570 | 0.110 |
Why?
|
| Middle Aged | 6 | 2025 | 27620 | 0.110 |
Why?
|
| Corpus Callosum | 1 | 2014 | 58 | 0.110 |
Why?
|
| Papillomaviridae | 2 | 2025 | 179 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2014 | 82 | 0.100 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 577 | 0.100 |
Why?
|
| Male | 8 | 2025 | 44578 | 0.100 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2014 | 152 | 0.100 |
Why?
|
| Nerve Net | 1 | 2014 | 394 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 761 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3479 | 0.060 |
Why?
|
| Carboplatin | 1 | 2025 | 322 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2025 | 479 | 0.050 |
Why?
|
| Aged | 3 | 2025 | 20469 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2024 | 321 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 148 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 288 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 63 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 359 | 0.040 |
Why?
|
| Immune System | 1 | 2022 | 101 | 0.040 |
Why?
|
| Adult | 3 | 2025 | 27953 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 140 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 572 | 0.040 |
Why?
|
| Pyramidal Tracts | 1 | 2014 | 15 | 0.030 |
Why?
|
| Pons | 1 | 2014 | 25 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 32 | 0.030 |
Why?
|
| Anisotropy | 1 | 2014 | 64 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 77 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2806 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7073 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2592 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 9108 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 629 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1322 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7645 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3832 | 0.020 |
Why?
|
| Child | 1 | 2014 | 7359 | 0.010 |
Why?
|